A Phase Ib, Open-Label Study of The Safety and Pharmacology of Atezolizumab (Anti PD-L1 Antibody) Administered in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Patients With BRAFV600-Mutation Positive Metastatic Melanoma

Trial Profile

A Phase Ib, Open-Label Study of The Safety and Pharmacology of Atezolizumab (Anti PD-L1 Antibody) Administered in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Patients With BRAFV600-Mutation Positive Metastatic Melanoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 06 Jul 2017 Planned primary completion date changed from 30 Jun 2017 to 28 Nov 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Updated safety and clinical activity results (n=34) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top